Terms: = Prostate cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
21 results:
1. Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant prostate cancer.
Nindra U; Hong JH; Balakrishnar B; Pal A; Chua W
Clin Genitourin Cancer; 2023 Feb; 21(1):183-193. PubMed ID: 35927195
[TBL] [Abstract] [Full Text] [Related]
2. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract] [Full Text] [Related]
3. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic assessment program for prostate cancer: Lessons learned after 2 years and degree of compliance to Canadian guidelines.
Shabana W; Kotb A; Tesolin D; Ibrahim MFK; Dolcetti K; Boucher A; Bassuony M; Ramchandar K; Zakaria AS; Elmansy H; Shahrour W
Arch Ital Urol Androl; 2021 Dec; 93(4):389-392. PubMed ID: 34933523
[TBL] [Abstract] [Full Text] [Related]
5. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
6. The role of erbb4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
7. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
[TBL] [Abstract] [Full Text] [Related]
8. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract] [Full Text] [Related]
9. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
[TBL] [Abstract] [Full Text] [Related]
10. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract] [Full Text] [Related]
11. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
Hsu FN; Yang MS; Lin E; Tseng CF; Lin H
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E902-8. PubMed ID: 21364123
[TBL] [Abstract] [Full Text] [Related]
12. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract] [Full Text] [Related]
13. Anti-erbb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies.
Vexler A; Lidawi G; Loew V; Barnea I; Karaush V; Lev-Ari S; Shtabsky A; Ben-Yosef R
Cancer Biol Ther; 2008 Jul; 7(7):1090-4. PubMed ID: 18443429
[TBL] [Abstract] [Full Text] [Related]
14. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
Ben-Yosef R; Starr A; Karaush V; Loew V; Lev-Ari S; Barnea I; Lidawi G; Shtabsky A; Greif Y; Yarden Y; Vexler A
Prostate; 2007 Jun; 67(8):871-80. PubMed ID: 17440944
[TBL] [Abstract] [Full Text] [Related]
15. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract] [Full Text] [Related]
16. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract] [Full Text] [Related]
17. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract] [Full Text] [Related]
18. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Agus DB; Akita RW; Fox WD; Lewis GD; Higgins B; Pisacane PI; Lofgren JA; Tindell C; Evans DP; Maiese K; Scher HI; Sliwkowski MX
Cancer Cell; 2002 Aug; 2(2):127-37. PubMed ID: 12204533
[TBL] [Abstract] [Full Text] [Related]
19. CI-1033, a pan-erbB tyrosine kinase inhibitor.
Slichenmyer WJ; Elliott WL; Fry DW
Semin Oncol; 2001 Oct; 28(5 Suppl 16):80-5. PubMed ID: 11706399
[TBL] [Abstract] [Full Text] [Related]
20. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract] [Full Text] [Related]
[Next]
